Introduction
Abnormal uterine bleeding (AUB) interferes with physical, emotional, and social well-being, impacting the quality of life of more than 10 million women in the USA. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Nearly one-third of all gynecologic office visits are related to AUB. 2, 8, 13 AUB also has substantial cost implications, with estimated annual direct costs in the USA ranging $1-$1.55 billion and indirect costs ranging $12-$36 billion. 12 Hysterectomy, a common surgical treatment of AUB, has significant morbidity, long recovery, and high associated health care costs. 7, 9, 14 Global endometrial ablation (GEA) provides a surgical alternative with reduced morbidity, cost, and recovery time. 3, 7, 8, 14, 15 NovaSure ® endometrial ablation (Hologic, Inc, Marlborough, MA, USA) utilizes a radiofrequency impedance-based GEA technology. Since the US Food and Drug Administration approval of NovaSure in 2001, 16 substantial data have been generated that support the favorable safety and efficacy profile for use of the procedure in premenopausal women for the treatment of AUB. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Compared to other GEA techniques, the NovaSure procedure has the fastest treatment time, requires no hormonal pretreatment, and can be performed at any time during the menstrual cycle within a hospital or office setting. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Although cost-effective treatments of AUB are particularly appealing in today's cost-conscious health care environment, which values safe and efficacious treatments that reduce the costs associated with inpatient care, 15 costs and cost-effectiveness information about surgical treatment of AUB with GEA and hysterectomy from a US payer perspective have been sparsely published. Cost effectiveness of the NovaSure procedure relative to other GEA modalities and hysterectomy has never been formally evaluated. In this study, we developed a health economic model to evaluate the cost effectiveness of AUB treatment with the NovaSure procedure versus other GEA modalities and versus hysterectomy from the US commercial and Medicaid payer perspectives.
Methods

Model structure and target population
A health state transition (semi-Markov) model was developed using TreeAge Pro 2013 (TreeAge Software, Inc, Williamstown, MA, USA). Three hypothetical cohorts of women receiving AUB interventions were simulated over 1-, 3-, and 5-year horizons in monthly iterations or "cycles" to evaluate clinical and economic outcomes for NovaSure treatment, other GEA modalities, and hysterectomy ( Figure 1 ).
Other GEA modalities include second-generation GEA techniques (eg, cryotherapy, microwave endometrial ablation, thermal balloon endometrial ablation, hydrothermal ablation) other than bipolar radiofrequency ablation with the NovaSure system. "Hysterectomy" includes laparoscopic/ robotic-assisted hysterectomy, vaginal hysterectomy, and abdominal hysterectomy.
The focus of the modeling analyses was specifically on the stratum of premenopausal women for whom childbearing is complete and who seek a permanent, nonreversible, one-time treatment option for their AUB with the two choices of GEA or hysterectomy. It is implicit that these women may have used medical management (eg, levonorgestrel intrauterine system [LNG-IUS], pharmacological therapy) prior to treatment for their AUB, per American College of Obstetricians and Gynecologists and other treatment guidelines. 1, 29 In some cases, these other forms of treatment may have failed or, for a variety of reasons, they were not a viable initial option. Regardless, the model analyses initiate on the specific day when each woman in the simulated cohorts underwent her GEA or hysterectomy procedure.
Model simulations begin at the point where AUB treatment is initiated. Site of procedure included office, ambulatory, and inpatient facilities, as naturalistically observed in the underlying claims data used to populate the model parameters. Average starting age in all three cohorts was assumed to be 42 years, consistent with the underlying clinical and economic data 30, 31 and demographically similar to women cohorts in other economic models of surgical AUB treatment. [32] [33] [34] [35] [36] Menopause was assumed to occur on or after age 52 (ie, beyond the 1-5-year base case analysis time frame and beyond the maximum 10-year time simulation the model was capable of generating for sensitivity analysis testing) and was not factored into the model calculations, also consistent with other economic models of surgical AUB treatment. In any given model cycle, patients either could remain in or move between 21 discrete health states to replicate the natural course of postsurgical AUB treatment over time. Time-varying transition probabilities, costs, and quality-of-life values were ascribed to each health state and differ according to the characteristics of the particular treatment options being compared. At the end of each simulation, incremental differences in cumulative total costs and outcomes between the treatments were used to generate metrics of cost effectiveness typically used by health care decision makers.
Two versions of the model were created -one containing clinical and economic data oriented from the US commercial health care payer perspective and the other from a US Medicaid perspective. Underlying clinical and cost data differed in the two versions of the model, but the structure and functional operation were identical, with the exception that the commercial payer perspective version of the model was programmed to generate outputs associated with work absence and short-term disability and the associated "indirect costs" from these productivity losses.
The approach used for developing the model is entirely consistent with other economic models of AUB treatment comparing GEA and hysterectomy that have been developed in recent years. [32] [33] [34] [35] [36] Data inputs and sources
Datatabase analyses
Data inputs for the model and the sources from which they were derived are listed in Tables 1-6 . Most clinical and economic data (including treatment patterns, health state transition probabilities, health care resource utilization, direct costs, and productivity costs) were primarily derived from de novo analyses of three large medical claims databases: 
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Miller et al These databases provide information on individuals covered by a variety of employer-sponsored private health insurance plans and employer-paid Medicare supplemental insurance and are considered nationally representative of persons with employer-sponsored health insurance with respect to geography, age, and gender. The database analyses underlying this study focused in a naturalistic, real-world manner on 63,482 women aged 30-55 years with diagnosed AUB who initiated treatment with GEA or hysterectomy (index event) during 2006-2010. Twelve months of continuous enrollment pre-and post-index event were required, and health care utilization and costs assessed in the year following treatment initiation. Probabilities and costs of reintervention were tracked for 3 years following GEA. Workplace absenteeism and short-term disability costs were reported for a subset of patients from the commercial database analyses. More detailed description of the methods and results of these database analyses has been published elsewhere. 30, 31, 37 The small amount of data pertaining to quality of life (ie, utilities) and mortality not obtainable from these database analyses were derived from published literature and various other published and unpublished sources, as documented in Tables 4 and 6 .
Because of the manner in which GEA insurance claims are coded (ie, no coding differentiation between GEA types/ techniques), model parameters pertaining to NovaSure were assumed to be identical to those of GEA, with two exceptions -NovaSure-specific efficacy and safety data (ie, treatment complication rates and reintervention rates) were derived from a literature review and synthesis of 16 published studies (2002-2012) of women utilizing NovaSure treatment for AUB. [18] [19] [20] [21] [23] [24] [25] 28, [38] [39] [40] [41] [42] [43] [44] [45] NovaSure treatment reintervention rates (Table 2 ) and treatment complication rates (Table 3) were found to be relatively low compared to those for other GEA modalities.
Interventions and reinterventions
As mentioned above, different types/techniques of GEA could not be discerned from coding of GEA payment claims within the claims database analyses, so other GEA was modeled as a composite of all GEA types/techniques. Firstgeneration endometrial ablation techniques were excluded from the data analyses. Similarly, hysterectomy was modeled as a composite of laparoscopic/robotic-assisted hysterectomy, vaginal hysterectomy, and abdominal hysterectomy as observed in real-world practice through the claims database analyses. Per the database analyses, a small probability of reintervention after NovaSure and other GEA with LNG-IUS was allowed in the model. Similarly, tranexamic acid also 
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As economic inputs to the model, direct costs of intervention and 30-day follow-up for NovaSure, other GEA, and hysterectomy are shown in Table 1 , as are the reintervention and 30-day direct costs. Direct costs of NovaSure patients were assumed to be the same as other GEA. Intervention/reintervention costs and associated 30-day follow-up costs encompass "all health care expenditure", not just gynecological-related health care expenditure. However, chronic monthly costs for patients in a postintervention/reintervention "well" health state are specifically gynecological-related health care expenditures. All post-intervention costs were assumed to remain constant indefinitely within a simulation, changing only when reintervention is encountered and new post-reintervention costs are ascribed. All cost estimates were derived from the MarketScan ® database analyses 30, 31, 37 and expressed as 2013 US dollars (adjusted where necessary using the Medical Care component of the US Consumer Price Index).
Health state utility values
Health state utility scores (between 0= death and 1= perfect health) were used to calculate quality-adjusted life-years (QALYs). As documented in Table 4 , utility data were derived from other published economic models of AUB which had 37 Due to data limitations, tranexamic acid monthly probability of reintervention was assumed to be the same as those for adjunctive/alternative pharmacotherapy (ie, non-IUD hormonal therapies).
† adjunctive/alternative pharmacotherapy comprises assorted non-IUD hormonal therapies used adjunctively after intervention/reintervention with novasure or other gea or alternatively after reintervention with lng-IUs. Abbreviations: aUB, abnormal uterine bleeding; gea, global endometrial ablation; IUD, intrauterine device; lng-IUs, levonorgestrel intrauterine system; se, standard error.
was included in the model as a reintervention option, but limited available claims data for tranexamic acid necessitated substituting some data pertaining to non-intrauterine device hormonal therapies as a proxy. Use of adjunctive/alternative pharmacotherapy with non-intrauterine device hormonal therapy, comprising the large array of available combination oral contraceptives, conjugated estrogens, and progestin-only pills, was accounted for in the model calculations as well. As summarized in Table 2 , three sets of reintervention probabilities and reintervention-type distributions are featured in the model pertaining to the 3 sequential years after initial AUB intervention. All values were held constant at the third-year values in the fourth and fifth year of the analyses.
complications
Probabilities of complications in the first month (30 days) post-intervention or reintervention are listed in Table 3 . Complications included are cervical occlusion, cervical trauma (including cervical lacerations and hematometra), uterine perforation, bowel perforation, fluid overload, pregnancy, pyometra, cervicitis, device complications; a subsequent AUB treatment within 30 days, an inpatient stay, or emergency room visit within 2 days of the intervention or reintervention procedure (excluding patients with an inpatient stay for that procedure). All complications data were derived from the MarketScan ® database analyses. 37 Due to data limitations, values for tranexamic acid are assumed to be the same as those for adjunctive pharmacotherapy (ie, non-IUD hormonal therapies). † adjunctive/alternative pharmacotherapy comprises assorted non-IUD hormonal therapies used adjunctively after intervention/reintervention with novasure or other gea or alternatively after reintervention with lng-IUs. Abbreviations: aUB, abnormal uterine bleeding; gea, global endometrial ablation; IUD, intrauterine device; lng-IUs, levonorgestrel intrauterine system; se, standard error.
obtained estimates from patient-reported outcome studies with quality-of-life assessments.
Work impairment
Work impairment was defined in the model as all-cause absence from work and work loss due to short-term disability. As inputs to the commercial payer version of the model, Table 5 shows the monthly probability of work absence or work loss from short-term disability and the corresponding number of days of lost work. These estimates were derived from the MarketScan ® database analyses.
30,31,37
Model analysis outcomes
Analytical results generated by the model include an assortment of comparative clinical and economic outcomes, with presentation of incremental cost-effectiveness ratios (ICERs) for NovaSure versus other GEA and NovaSure versus hysterectomy. Clinical outcomes include total and incremental QALYs, total and incremental cases of treatment complications, and total and incremental reinterventions and reintervention hysterectomies (for the NovaSure versus other GEA analyses only). Work productivity outcomes (US commercial payer perspective only) included total and incremental number of work days lost due to worker absence and short-term disability. Economic outcomes include total and incremental direct costs due to worker absence and short-term disability. Cost-effectiveness outcomes include cost per QALY, cost per complication case avoided, cost per reintervention avoided, cost per reintervention hysterectomy avoided, and cost per work day saved.
analysis time horizon
Although the model was programmed to simulate any time horizon from 1 month up to 5 years (and 10 years as a sensitivity analysis), we selected a few key time points over a 5-year horizon that would be of universal interest, and they are referred to here as Year 1, Year 3, and Year 5.
sensitivity analyses
A variety of univariate and probabilistic sensitivity analyses (PSAs) were conducted to test the robustness of model parameter values and their impact on the ICERs. Using a second-order Monte-Carlo simulation (1,000 iterations), PSA was conducted on the model's primary cost-effectiveness outcome and incremental cost per incremental QALY. The parameter values of each probability distribution were calculated from the mean and standard error of the model input parameters. By drawing randomly from those distributions, a large number of estimates of costs, QALYs, and ICERs were generated, thus testing the consequences of varying input parameters. Targeted one-way deterministic sensitivity analyses were performed on the ICERs featuring complications, reinterventions, reintervention hysterectomies, and work productivity. A 10-year analysis scenario was performed to test robustness of the model estimates over long time horizons.
Discounting
Both costs and survival estimates (ie, QALYs) were discounted at an annual discount rate of 3%.
Results
Results of the model analyses show lower total direct costs for NovaSure-treated patients than for patients treated with other GEA modalities or hysterectomy over all time frames under both the commercial payer and Medicaid perspectives ( Table 7) . As an example, Year 1 direct costs for NovaSure patients were $6,602 and $4,419 in the commercial payer and Medicaid payer perspectives, respectively, which were substantially less than corresponding costs for GEA patients ($7,180 and $6,158, respectively) and less than one-half of the corresponding costs of hysterectomy ($13,221 and $12,716, respectively). The cost differential between the treatments narrowed somewhat over time, but even at Year 3 and Year 5 NovaSure costs were still one-third less than hysterectomy costs. Looking at the incremental differences between NovaSure treatment costs and the comparators, direct cost savings from NovaSure treatment versus other GEA modalities ranged from $578 to $1,309 (commercial payer perspective) and $1,739 to $4,372 37 Due to data limitations, values for tranexamic acid are assumed to be the same as those for adjunctive pharmacotherapy (ie, non-IUD hormonal therapies).
† adjunctive/alternative pharmacotherapy comprises assorted non-IUD hormonal therapies used adjunctively after intervention/reintervention with novasure or other gea or alternatively after reintervention with lng-IUs. Abbreviations: aUB, abnormal uterine bleeding; gea, global endometrial ablation; IUD, intrauterine device; lng-IUs, levonorgestrel intrauterine system; se, standard error. (Medicaid perspective) in Year 1 and Year 5, respectively. More dramatic were the estimated potential cost savings for NovaSure treatment versus hysterectomy, which ranged from $6,619 to $6,208 (commercial payer perspective) and $8,297 to $9,259 (Medicaid perspective) in Year 1 and Year 5, respectively. In the commercial payer perspective analysis, model estimates show that NovaSure-treated patients should experience up to 11% fewer days of work absence and short-term disability when compared with other GEA patients, and up to 47% fewer work days lost compared with hysterectomy patients. For example, in the 1-year analysis, NovaSure patients lost 29.4 days work versus 29.7 and 55.3 work days lost for other GEA and hysterectomy patients, respectively. Corresponding indirect costs were $7,412 for NovaSure patients versus $7,491 and $13,924 for other GEA and hysterectomy patients, respectively.
Quality-of-life outcomes, measured in terms of QALYs, were higher for NovaSure-treated patients than for those treated with other GEA over all time frames under both the commercial payer and Medicaid perspectives (Table  7) . For NovaSure versus hysterectomy, QALYs were higher for NovaSure in the Year 1 analysis results, but favorability shifted to hysterectomy in the Year 3 and Year 5 resultsa phenomenon attributable to the inherently higher long-term utility weights assigned to hysterectomy, but also due to the cumulative disutility experienced by NovaSure and other GEA patients undergoing repeat ablation and other forms of reintervention naturally avoided by hysterectomy patients. However, the magnitude of the difference in QALYs between NovaSure treatment and hysterectomy is quite small -even by Year 5, QALYs are only about 3% (0.12 QALYs) lower for NovaSure treatment in both the commercial payer and Medicaid scenarios. 
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Miller et al Table 7 cost-effectiveness analysis results Clinical outcomes (ie, reinterventions and occurrence of intervention/reintervention complications) from the modeling analyses bear special mention. From the NovaSure versus other GEA analyses, results show NovaSure-treated patients associated with a 43%-71% reduction in need for reintervention by re-ablation, hysterectomy, or nonsurgical means. Looking at reintervention hysterectomies alone, NovaSuretreated patients had 80% fewer reintervention hysterectomies in the commercial payer analyses, with even larger reductions estimated in the Medicaid analyses. Furthermore, the model predicts 69%-88% fewer intervention/reintervention complications for NovaSure-treated patients versus other GEA modalities, and 82%-91% fewer complications versus hysterectomy. For example, whereas 17.1% of other GEA patients and 35.6% of hysterectomy patients had complications in the first year under the commercial payer perspective, only 4.3% of NovaSure patients had complications. The gap narrows over time as the initial complications of hysterectomy remain constant, while reintervention complications for NovaSure and GEA patients gradually accumulate. However, even by Year 5, NovaSure-treated patients had 69% fewer complications than other GEA patients and 81% fewer complications than hysterectomy patients. Results were similar under the Medicaid perspective.
Model
Cost-effectiveness metrics show NovaSure treatment as economically dominant over other GEA modalities in all circumstances. This represents the potential for improved outcomes among women treated with the NovaSure system (ie, greater QALYs, fewer complications, fewer reinterventions, or fewer work days lost) at lower cost compared with other GEA modalities. Similar results were shown for the NovaSure procedure versus hysterectomy, where NovaSure was typically the dominant strategy (ie, always conferring greater benefit at lower cost). Exceptions were found for the cost-effectiveness metrics involving QALYs in scenarios for Years 3 and 5, where NovaSure treatment conferred cost savings compared with hysterectomy but with reduced benefits (ie, fewer QALYs), resulting in decremental costeffectiveness ratios ranging from $51,123 to $118,846 saved per QALY lost (commercial perspective) and from $80,902 to $187,884 saved per QALY lost (Medicaid perspective).
Results were not highly sensitive to univariate and probabilistic variation in the parameter values -that is, the changes did not appreciably alter the ICERs (including economic dominance), nor did they generally affect conclusions about the cost effectiveness of the NovaSure procedure. Focusing specifically on the cost-per-QALY ICERs in the 5-year scenario, where the analysis results were somewhat anomalous 
Discussion
Results of this economic modeling study of AUB show that the direct and indirect costs of NovaSure treatment of AUB are substantially lower than those for other GEA modalities and hysterectomy over short (1-year) and longer (5-year) time horizons, and under both commercial payer and Medicaid perspectives. By 5 years after intervention, direct costs for NovaSure patients are $1,300-$4,400 less compared to those for other GEA patients, and $6,200-$9,300 less compared with hysterectomy patients. Similar results were found for indirect costs, under the commercial payer perspective. Combining these cost savings with clinical and quality-oflife benefits of treatment yielded cost-effectiveness metrics favoring the NovaSure procedure over other GEA modalities and hysterectomy as an AUB treatment strategy. In almost all scenarios analyzed, NovaSure treatment was found to be the economically dominant strategy over other GEA and hysterectomy -that is, NovaSure treatment confers better clinical outcomes and quality-of-life benefits at less cost.
A conservative estimate of the annual indirect economic costs of AUB in the USA is $12 billion, 12 which reveals impaired work productivity due to AUB having substantial economic implications, both for individual women and for society. 12, [46] [47] [48] [49] [50] [51] From an employer's perspective, AUB is an expensive condition, and choice of treatments can profoundly affect the direction of those costs. 30, 46 Results generated by our model indicate that in the initial year following surgical treatment of AUB, NovaSure-treated patients had almost 26 fewer days of work absence and short-term disability leave compared with hysterectomy patients, leading to an indirect cost (ie, work loss) savings of greater than $6,500. The incremental difference narrows over time, but even by 5 years, NovaSure accounts for more than 30% fewer days of work loss and associated indirect costs. As would be expected, given the technical similarities between the NovaSure procedure and other GEA modalities, comparative results for NovaSure treatment versus other GEA are more modest.
The Medicaid perspective analyses from this study are particularly relevant given recent expansion of the US Medicaid program and the creation of new state-based and federally facilitated competitive marketplaces, or Affordable Insurance Exchanges. Using the average of published AUB prevalence statistics of about 20%, [9] [10] [11] [12] it follows that a sizeable number of newly eligible women in the expanded Medicaid program will have AUB, many of whom will go on to receive costly pharmacologic and surgical treatments. Hysterectomies will be of particular financial concern, not only because of their high cost but also because they comprise about 27% of the total pharmacologic and surgical AUB interventions that are performed each year in the Medicaid population. 31, 37 Results of our Medicaid perspective analyses suggest that the NovaSure procedure may save substantial costs -as much as $8,300 per patient in the initial year following intervention and as much as $9,300 by 5 years. Consequently, state-based and federally facilitated exchanges may focus intently on GEA (particularly on less costly, in-office procedures with the NovaSure procedure) as ways to reduce costs.
Limitations
The focus of the analyses was on women who sought and underwent GEA (including NovaSure) or hysterectomy as their chosen AUB treatment option. The analyses did not extend to the greater realm of medical management of AUB and, therefore, we did not evaluate the cost effectiveness of LNG-IUS and pharmacologic therapies in comparison with NovaSure, other GEA, and hysterectomy. There were some data limitations in our study, most of which are inherently tied to using an administrative health care database as the primary data source for the economic model. First, as observed in other retrospective claims database analyses, the most completely recorded data are those that affect reimbursement. Hence, the capture of expenditures is highly accurate, but data on comorbidities and disease severity may not be as carefully recorded. Second, procedure coding in claims data is limited in its ability to differentiate specific types/techniques of GEA or hysterectomy. Analyses of these different procedure types may have revealed differences in clinical and cost outcomes from the model, but it is not possible to speculate about the magnitude and direction of those differences. Third, due to the structure of the underlying claims database analyses, we did not conduct age-stratified subgroup analyses with the model, although patient age may correlate with clinical and economic outcomes. Fourth, the indirect costs included in this analysis are not exhaustive. For example, absenteeism and short-term disability claims do not include transportation costs to and from medical appointments, caregiver time, childcare time, long-term disability, or reduced productivity while at work. Finally, the model's underlying data pertained to patients with commercial insurance or Medicaid supplemental insurance; therefore, the analyses results may not represent all patients with AUB, especially those uninsured or covered under other Medicaid programs. We also note that although the literature provided health state utility values sufficient for use in the economic model, they are mostly from older studies, some of which predate the advent of second-generation endometrial ablation technologies (notably, the extensively referenced 1998 cost-utility analysis by Sculpher). 52 QALY metrics in the analysis results were fairly sensitive to changes in utility values, but it is difficult to say how the results would have changed if more current, robust utility data were available.
Conclusion
The role of GEA in the surgical treatment of AUB has grown in the USA and the NovaSure procedure has secured a strong position in the AUB treatment market. This high regard for NovaSure treatment is reflected by the results of our economic model, which show strong financial favorability for the NovaSure procedure over other GEA modalities and over hysterectomy from both the commercial payer and Medicaid payer perspectives. Results from this study will interest the US commercial health payers and self-insured employers seeking cost-effective treatment for AUB. Similarly, new federal mandates for Medicaid expansion are likely to focus on the attractiveness of outpatient treatments like the NovaSure procedure and other GEA modalities to reduce Medicaid costs.
